Instalab

The TMG Supplement Tradeoff: It Lowers One Heart Risk Marker While Raising Another

TMG (trimethylglycine, also called betaine) does something frustrating. According to meta-analysis data, it reliably lowers homocysteine by about 1.3 µmol/L, a marker linked to cardiovascular risk. But it simultaneously raises total and LDL cholesterol, particularly at doses of 4 grams per day or higher. That's not a minor footnote. It's the central tension in the TMG story, and it should shape how you think about supplementing.

Marketed for everything from heart health to gym performance to liver support, TMG is a naturally occurring compound involved in methylation, osmotic balance, and metabolism. The animal research looks impressive. The human research looks far more modest, and sometimes contradictory. Here's where things actually stand.

The Animal Data Looks Great. The Human Data Doesn't Match.

In rodent studies, betaine improves glucose tolerance, insulin action, liver fat, and obesity-related metabolic disturbances through several pathways, including AMPK activation, FGF21 signaling, fat browning, and gut microbiota changes. On paper, it sounds like a metabolic wonder compound.

But when researchers tested high-dose betaine (around 10 g/day) in people with prediabetes, it only modestly lowered insulin response to a glucose load. It did not improve insulin sensitivity measured by the gold-standard clamp method, and it did not reduce liver fat. That same trial also found increased total cholesterol, reinforcing the lipid concern.

In obese adults placed on a calorie-restricted diet, 6 g/day of betaine for 12 weeks produced no improvement in weight or body composition compared to placebo. If you're hoping TMG will meaningfully move the needle on metabolic health or weight loss, the human evidence so far doesn't support that.

The Dose Makes the Tradeoff

The relationship between TMG dose and its effects isn't linear in a helpful way. Higher doses amplify both the potential benefit (homocysteine reduction) and the potential harm (cholesterol increases).

Dose RangeHomocysteine EffectLipid EffectNotes
< 4 g/dayLikely beneficialLess lipid worseningMay offer the best risk-benefit balance
≥ 4 g/dayBeneficial (~−1.3 µmol/L)Raises total and LDL cholesterolConsistent finding across meta-analysis and trial data
~10 g/dayBeneficialIncreased total cholesterol observedUsed in prediabetes trial; no insulin sensitivity or liver fat improvement

The research suggests that staying below 4 g/day may let you capture the homocysteine-lowering benefit while minimizing lipid problems. But "minimizing" isn't the same as "eliminating," and no long-term trials have confirmed this is a safe sweet spot.

Does It Actually Help in the Gym?

The performance claims around TMG are the most overhyped relative to the evidence. A broader narrative review of the sports research confirms that marketing has outpaced science here.

That said, there are a few signals worth noting. In young athletes, 2.5 g/day for two weeks increased repetition performance and produced a more anabolic hormone profile acutely after resistance training. Animal studies and limited human trials suggest possible improvements in body composition when combined with training.

But the overall picture is weak:

  • Evidence for increased strength or power is not convincing
  • There's no clear clinical consensus on body composition benefits
  • Long-term safety in athletic populations remains undefined

If you're already training seriously, 2.5 g/day might offer a marginal edge in workout volume. But don't expect TMG to function like creatine or any other well-validated ergogenic aid. The evidence simply isn't there yet.

Who Should Be Most Cautious

TMG is generally well tolerated in the short term. But "well tolerated short term" is doing a lot of heavy lifting in supplement marketing, and it shouldn't be confused with "safe for everyone."

  • People with cardiovascular risk: The LDL and total cholesterol increases are the clearest concern. If you already have elevated cholesterol or are managing heart disease risk, adding a supplement that reliably raises lipids at common doses deserves serious scrutiny, not casual experimentation.
  • People with chronic kidney disease: Betaine plays physiological roles in CKD and aging, and there's theoretical reason to think it could help. But human trial data in these populations is sparse. "Theoretical benefit" and "proven benefit" are very different things.
  • People stacking multiple supplements: One reported case of fatal multi-organ failure involved betaine among many unregulated anabolic agents. Causality to TMG alone is unclear, but it highlights a real risk: when you combine poorly studied compounds, you lose the ability to predict interactions.

Long-term safety data, especially for older adults and those with kidney disease, simply doesn't exist in sufficient quantity to make confident recommendations.

A Practical Framework Before You Buy

TMG is biologically important. Your body uses it. That doesn't automatically mean supplementing more of it produces better outcomes, and the human trial data makes that clear.

Your SituationWhat the Research Suggests
Elevated homocysteine, normal lipidsLow-dose TMG (< 4 g/day) may help, but monitor cholesterol
Elevated cholesterol or cardiovascular riskThe lipid tradeoff makes TMG a questionable choice
Looking for metabolic or weight loss supportHuman trials show no meaningful benefit
Serious athlete wanting a performance edge2.5 g/day may modestly improve training volume; don't expect much
CKD or older adultNot enough human data to recommend or warn against confidently

If you decide to try TMG, keep the dose at or below 4 g/day, get your lipids checked before and after a few months of use, and be honest with yourself about whether you're seeing results or just hoping the animal data translates. Right now, for most people, it's a supplement with a real biological role but an unresolved risk-benefit profile.

References

72 sources
  1. Kacerova, T, Yates, AG, Dai, J, Shepherd, D, Pires, E, De Jel, S, Gong, Q, Schiffer, E, Jernerén, F, Olsen, T, De Jager Loots, CA, Refsum, H, Smith, AD, Mccullagh, JSO, Anthony, DC, Probert, FAlzheimer's & Dementia : The Journal of the Alzheimer's Association2025
  2. Smith, AD, Smith, SM, De Jager, CA, Whitbread, P, Johnston, C, Agacinski, G, Oulhaj, a, Bradley, KM, Jacoby, R, Refsum, HPloS One2010
  3. Batista, KS, Cintra, VM, Lucena, PAF, Manhães-de-castro, R, Toscano, AE, Costa, LP, Queiroz, MEBS, De Andrade, SM, Guzman-quevedo, O, Aquino, JSNutrition Reviews2022
  4. Bønaa, KH, Njølstad, I, Ueland, PM, Schirmer, H, Tverdal, a, Steigen, T, Wang, H, Nordrehaug, JE, Arnesen, E, Rasmussen, KThe New England Journal of Medicine2006
30-min video call

Your results, explained.

with Dr. Steven Winiarski

Most people leave their doctor’s office with more questions than answers. A longevity physician will actually sit with your results and give you a clear, written plan.

★★★★★“Over several months of testing and tweaking my medication, I’ve lowered my ApoB to 60 mg/dL, placing me in a low-risk category. The sense of relief is incredible.”Ken Falk, Instalab member
$150 vs $300+ specialist visit · HSA/FSA eligible
30-min video call

Your results, explained.

with Dr. Steven Winiarski

Most people leave their doctor’s office with more questions than answers. A longevity physician will actually sit with your results and give you a clear, written plan.

★★★★★“Over several months of testing and tweaking my medication, I’ve lowered my ApoB to 60 mg/dL, placing me in a low-risk category. The sense of relief is incredible.”Ken Falk, Instalab member
$150 vs $300+ specialist visit · HSA/FSA eligible
The TMG Supplement Tradeoff: It Lowers One Heart Risk Marker While Raising Another | Instalab